8-K 1 a8-k.txt 8-K ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 9, 2000 ------------------------- GENOME THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) MASSACHUSETTS 0-10824 04-2297484 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification Number) 100 BEAVER STREET WALTHAM, MASSACHUSETTS 02453 (Address of principal executive offices, including zip code) (781) 398-2300 (Registrant's Telephone number including area code) ------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- PAGE 1 OF 4 PAGES. Item 5. OTHER EVENTS On June 7, 2000, Genome Therapeutics Corp. issued a press release announcing that the Company has secured rights to obtain worldwide exclusive access to certain patented Single Nucleotide Polymorphisms (SNPs) detection technology from Northeastern University. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1. -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENOME THERAPEUTICS CORP. By /s/ Philip V. Holberton --------------------------- Name: Philip V. Holberton Title: Chief Financial Officer Date: June 9, 2000 EXHIBIT INDEX ------------- 99.1 Press Release dated June 7, 2000